Today’s the last day of our online International Conference on Group B Strep (ICGBS) 2021! We hope you will join this collaboration of over 440 registrants representing 42 countries for today’s presentations and also to view any presentations you missed from Day 1 and Day 2 which can all be found in our Presentation Gallery. Registration is free, quick and easy at gbsi.me/ICGBS2021
Today’s presentations (uploaded for ease of viewing from any time zone):
July 22 – Novel Approaches and Research
Characterization of a novel GBS colonization factor – Laura C. Cook, PhD
Investigating mechanisms of persistent Group B Streptococcus colonization after intrapartum antibiotic prophylaxis treatment – Macy E. Pell, BS, PhD candidate
Antibiotic adjuvants: rejuvenating our current arsenal of antimicrobials against Group B Streptococcus – Sabrina K. Spicer, BS, current PhD student
Molecular characterization of invasive Group B streptococcus in South Africa, 2019-2020 – Buhle Ntozini, BMedSci (Hons)
A mouse model reproducing the pathophysiology of neonatal group B streptococcal disease – Elva Bonifácio Andrade, PhD
Commensal Streptococcus salivarius overcomes suppression of growth by pathogenic Group B Streptococcus – Rebecca E. Moore, BS, MS
A type VII secretion system in Group B Streptococcus mediates cytotoxicity and virulence – Brady Spencer, PhD
Please be sure to check out our virtual Research Wall to learn of GBS research efforts worldwide!
Best!
Marti
(Ms.) Marti Perhach
CEO/Cofounder
Group B Strep International
+1 909 620-7214
marti.perhach@gbs-intl.org
groupbstrepinternational@gmail.com
www.groupbstrepinternational.org
Promoting awareness and prevention of group B strep disease in babies before birth through early infancy
CHIFA profile: Marti Perhach is the CEO and Founder of Group B Strep International (GBSI) in the USA. marti.perhach AT gbs-intl.org